| 证券代码 | ARGS.O |
| 证券名称 | Argos Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-02-07 |
| 首发价格(元) | 8 USD |
| 首发数量(股) | 5625000 |
| 首发募资额(元) | 45,000,000.00 USD |
| 首发主承销商 | JMP Securities LLC,Piper Jaffray & Co.,Stifel Nicolaus & Company |
| 货币单位 | USD |
| 公司名称 | Argos Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 4233 Technology Drive, Durham, North Carolina, USA |
| 成立日期 | 1997-05-08 |
| 董事会主席 | Hubert Birner |
| 公司属地 | United States 美国 |
| 公司网址 | www.argostherapeutics.com |
| 电话 | +1 (919) 287-6300 |
| 传真 | - |
| 公司简介 | Argos Therapeutics, Inc. was incorporated in the State of Delaware on May 8, 1997. The Company is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary precision immunotherapy technology platform called Arcelis. |